| First Author | Stewart DJ | Year | 2014 |
| Journal | J Natl Cancer Inst | Volume | 106 |
| Issue | 1 | Pages | djt356 |
| PubMed ID | 24309006 | Mgi Jnum | J:206970 |
| Mgi Id | MGI:5553419 | Doi | 10.1093/jnci/djt356 |
| Citation | Stewart DJ (2014) Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106(1):djt356 |
| abstractText | Wnt/beta-catenin alterations are prominent in human malignancies. In non-small cell lung cancer (NSCLC), beta-catenin and APC mutations are uncommon, but Wnt signaling is important in NSCLC cell lines, and Wnt inhibition reduces proliferation. Overexpression of Wnt-1, -2, -3, and -5a and of Wnt-pathway components Frizzled-8, Dishevelled, Porcupine, and TCF-4 is common in resected NSCLC and is associated with poor prognosis. Conversely, noncanonical Wnt-7a suppresses NSCLC development and is often downregulated. Although beta-catenin is often expressed in NSCLCs, it was paradoxically associated with improved prognosis in some series, possibly because of E-cadherin interactions. Downregulation of Wnt inhibitors (eg, by hypermethylation) is common in NSCLC tumor cell lines and resected samples; may be associated with high stage, dedifferentiation, and poor prognosis; and has been reported for AXIN, sFRPs 1-5, WIF-1, Dkk-1, Dkk-3, HDPR1, RUNX3, APC, CDX2, DACT2, TMEM88, Chibby, NKD1, EMX2, ING4, and miR-487b. AXIN is also destabilized by tankyrases, and GSK3beta may be inactivated through phosphorylation by EGFR. Preclinically, restoration of Wnt inhibitor function is associated with reduced Wnt signaling, decreased cell proliferation, and increased apoptosis. Wnt signaling may also augment resistance to cisplatin, docetaxel, and radiotherapy, and Wnt inhibitors may restore sensitivity. Overall, available data indicate that Wnt signaling substantially impacts NSCLC tumorigenesis, prognosis, and resistance to therapy, with loss of Wnt signaling inhibitors by promoter hypermethylation or other mechanisms appearing to be particularly important. Wnt pathway antagonists warrant exploration clinically in NSCLC. Agents blocking selected specific beta-catenin interactions and approaches to increase expression of downregulated Wnt inhibitors may be of particular interest. |
